
Clinical trial shows 15-day Paxlovid regimen safe but adds no clear benefit for long COVID
In a clinical trial conducted by Stanford Medicine investigators and their colleagues, a 15-day course of Paxlovid—an antiviral drug combination targeting SARS-CoV-2, the virus that causes COVID-19—proved safe as an extended-duration ...
Jun 7, 2024
0
71